Drug Trial Radar · NCT02323126
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Feb 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
64
Actual
Start
Feb 9, 2015
Primary completion
Sep 23, 2019
Study completion Feb 5, 2021
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Dec 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in previously treated NSCLC patients
Conditions
- Non Small Cell Lung Cancer
Interventions
EGF816Drug
EGF816 150 mg once daily (QD) administered orally as a capsule
INC280Drug
INC280 400 mg twice daily (BID) administered orally as a tablet
NivolumabDrug
Nivolumab 3 mg/kg every 2 weeks (Q2W) administered by intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Rate at 6 Months Per RECIST v1.1Time frame: 6 months
Locations
13 sites in 8 countries. Site status is shown where the registry gives one.
University of Texas MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)
Houston, Texas
Novartis Investigative Site
Camperdown, New South Wales, Australia
Novartis Investigative Site
Chermside, Queensland, Australia
Novartis Investigative Site
La Tronche, France
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Perugia, PG, Italy
Novartis Investigative Site
Aviano, PN, Italy
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Málaga, Andalusia, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Alicante, Valencia, Spain
Novartis Investigative Site
Chur, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.